Follow

BioStock: Strong first half of 2020 for Scandion Oncology

06 August 2020 - 11:25

Ravaged by a pandemic, the first half of 2020 has not been a walk in the park for most companies. However, when looking at the year so far for Danish biotech company Scandion Oncology, the obstacles put in place by mother nature do not seem to have greatly affected the company, which has been able to reach several important milestones within its drug development. BioStock spoke to Scandion Oncology’s CEO Nils Brünner for a review of the year so far and what to look forward to in the months ahead.

Read the full interview with Nils Brünner, CEO of Scandion Oncology, at biostock.se

https://www.biostock.se/en/strong-first-half-of-2020-for-scandion-oncology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date